Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Press Releases
Date Title
09/13/19 Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D. Printer Friendly Version
07/30/19 Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis Printer Friendly Version
07/29/19 Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute Printer Friendly Version
07/25/19 Alkermes Plc Reports Second Quarter 2019 Financial Results Printer Friendly Version
07/18/19 Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results Printer Friendly Version
Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

Statement of changes in beneficial ownership of securities

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Report of unscheduled material events or corporate event